16-week Flexible vs. 8-week Semaglutide Titration

Status Recruiting

Clinical Trial Summary

Semaglutide is a Glucagon Like Peptide 1 (GLP-1) receptor agonist recently approved in Israel to improve glycemic control in patients with type 2 diabetes mellitus. Semaglutide is currently administered as a weekly subcutaneous injection.Treatment with semaglutide is associated with the occurrence of gastrointestinal adverse events (GI-AEs) commonly observed during GLP-1 receptor agonist treatment. The most common adverse reactions, reported in ≥5% of patients treated with semaglutide are nausea, vomiting, diarrhea, abdominal pain and constipation.

In this trial we plan to explore the effect of a slower titration regimen of semaglutide vs. the current label-recommended dose escalation regimen on the occurrence of GI-AEs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04447859
Study type	Interventional
Source	Tel-Aviv Sourasky Medical Center
Contact	Roy Eldor, MD PhD
Phone	+972-52-736-0680
Email	roye@tlvmc.gov.il
Status	Recruiting
Phase	Phase 3
Start date	February 23, 2020
Completion date	September 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04101669` - EndoBarrier System Pivotal Trial(Rev E v2)	N/A
Not yet recruiting	`NCT06327711` - Benefits of Nutritional Ingredients for Type 2 Diabetes	N/A
Recruiting	`NCT04164602` - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Completed	`NCT05915338` - Training on Using ıInsulin in Patients With Type 2 Diabetes
Not yet recruiting	`NCT04998461` - Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells
Not yet recruiting	`NCT04880005` - Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid	N/A
Recruiting	`NCT05365529` - Time-Restricted Eating for Type II Diabetes: TRE-T2D	N/A
Recruiting	`NCT03958591` - Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification	Phase 4
Completed	`NCT05284071` - Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation	N/A
Recruiting	`NCT05501093` - Diabetes Reversal and the Subgingival Microbiota
Active, not recruiting	`NCT05784220` - The Canadian Diabetes Prevention Program	N/A
Active, not recruiting	`NCT04286555` - Dietary Approaches to Stop Hypertension for Diabetes	N/A
Completed	`NCT05076656` - Epigenetic and Microbiota Modifications	Early Phase 1
Completed	`NCT04423302` - Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT)	N/A
Completed	`NCT05928637` - A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150	Phase 1
Active, not recruiting	`NCT04660630` - A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias	N/A
Recruiting	`NCT03435328` - Hyposalivation Response To Transcutaneous Electrical Nerve Stimulation In Diabetic Type 2 Patients	N/A
Not yet recruiting	`NCT03968354` - NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
Terminated	`NCT04819256` - Primary Care Based Integrated Community Care Team Intervention	N/A
Recruiting	`NCT05629221` - Organisational Models Supported by Technology for the Management of Diabetic Disease and Its Complications in a Diabetic Clinic Setting. A Randomised Controlled Trial Targeting Type 2 Diabetes Individuals With Non-ideal Glycemic Values	N/A